| Document |
Document Title |
|
WO/2019/018853A1 |
The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
|
|
WO/2019/010715A1 |
The present invention relates to the technical field of herbicide crystallisation processes, and relates in particular to a dicarfentrazone-ethyl crystalline form E, and a preparation method therefor and a use thereof. The X-ray powder d...
|
|
WO/2019/010717A1 |
The present invention relates to the technical field of herbicide crystallisation processes, and relates in particular to a dicarfentrazone-ethyl crystalline form C, and a preparation method therefor and a use thereof. The X-ray powder d...
|
|
WO/2019/010718A1 |
The present invention relates to the technical field of herbicide crystallisation processes, and relates in particular to a dicarfentrazone-ethyl crystalline form B, and a preparation method therefor and a use thereof. The X-ray powder d...
|
|
WO/2019/010716A1 |
The present invention relates to a dicarfentrazone-ethyl crystalline form D, and a preparation method therefor and a use thereof. The X-ray powder diffraction pattern of the dicarfentrazone-ethyl crystalline form D has characteristic pea...
|
|
WO/2019/014308A1 |
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...
|
|
WO/2019/009412A1 |
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...
|
|
WO/2019/001361A1 |
A piperic acid derivative and preparation and an application thereof. The structure of the derivative is as shown in general formula I. The compound of general formula I has excellent pesticidal, miticidal, and bactericidal activities an...
|
|
WO/2019/004584A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. The compound according to the present invention is used as an organic layer of an organic electroluminescent device and, pref...
|
|
WO/2019/000237A1 |
Provided are pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. Provided is also use of the compounds described herein in the potential treatment or prevention of neurological and...
|
|
WO/2019/005589A1 |
The present invention is directed to 5-(pyridine-3-yl)oxaxole compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the ...
|
|
WO/2019/001379A1 |
The present invention relates to an indazole compound for use in inhibiting kinase activity, and relates to a preparation and use thereof. Specifically disclosed in the present invention is an indazole compound represented by formula (I)...
|
|
WO/2019/000236A1 |
Disclosed are pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor, uses of the compounds described herein in the potential treatment of prevention of neurological and psychiatric di...
|
|
WO/2019/005587A1 |
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the pot...
|
|
WO/2019/005588A1 |
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the pot...
|
|
WO/2018/235966A1 |
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/230528A1 |
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...
|
|
WO/2018/225018A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2018/217631A1 |
The present disclosure provides compositions including a α4β2 nAChR antagonist, pharmaceutical compositions including a α4β2 nAChR antagonist, methods of making the compositions or pharmaceutical compositions, methods of treatment of...
|
|
WO/2018/214812A1 |
The present invention relates to a compound used as an autophagy regulator, and a preparation method therefor and uses thereof. Particularly, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt...
|
|
WO/2018/210729A1 |
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...
|
|
WO/2018/211442A1 |
The present invention relates to 4-substituted amidine derivatives of the general formula (I), wherein A1-A4, D, L, Q, R7, R7' and integer's v and w have the meanings as defined in description. The invention further relates to methods fo...
|
|
WO/2018/207881A1 |
To provide a compound that can exert a BET family protein-inhibiting effect and is likely to be useful as a prophylactic or therapeutic agent for autoimmune diseases and/or inflammatory diseases (for example, rheumatoid arthritis, multip...
|
|
WO/2018/201524A1 |
An amorphous biscarfentrazone and a preparation method and use thereof are provided. The X-ray powder diffraction pattern of the amorphous biscarfentrazone is free of acute diffraction peaks, and preferably is substantially as shown in F...
|
|
WO/2018/201939A1 |
The present invention relates to a prodrug of a benzoindazole derivative and a pharmaceutically acceptable salt thereof, a preparation method therefor, and an application thereof. The benzoindazole derivative prodrug has a general struct...
|
|
WO/2018/201523A1 |
An amorphous oxacillin fluridone and a preparation method, herbicidal composition and use thereof are provided. The X-ray powder diffraction pattern of the amorphous oxacillin fluridone is free of acute diffraction peaks, and preferably ...
|
|
WO/2018/201272A1 |
This invention concerns a process for the manufacture of carboxylic acids or carboxylic acid derivatives and a process for the manufacture of agrochemically and pharmaceutically active compounds comprising the process for the manufacture...
|
|
WO/2018/202677A1 |
This invention concerns a process for the manufacture of carboxylic acids or carboxylic acid derivatives and a process for the manufacture of agrochemically and pharmaceutically active compounds comprising the process for the manufacture...
|
|
WO/2018/204661A1 |
Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compos...
|
|
WO/2018/199284A1 |
The present invention provides a method for producing a difluoromethylene compound useful in the field of pharmaceuticals and for producing an intermediate of the compound. Specifically, the present invention provides a method for produc...
|
|
WO/2018/197714A1 |
The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof. The compounds are useful in the treatment of cancers.
|
|
WO/2018/197692A1 |
The present disclosure relates to fungicidal active compounds, more specifically to heteroarylphenylaminoquinolines and analogues thereof, processes and, intermediates for their preparation and use thereof as fungicidal active compound, ...
|
|
WO/2018/157190A9 |
The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human sub...
|
|
WO/2018/193385A1 |
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to metho...
|
|
WO/2018/195123A1 |
The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of ...
|
|
WO/2018/195439A2 |
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
|
|
WO/2018/192046A1 |
Disclosed are a triazolesulcotrione crystal form C, a preparation method therefor, and a use thereof. The triazolesulcotrione crystal form C has an X-ray powder diffraction spectrum with characteristic peaks at a diffraction angle of 2θ...
|
|
WO/2018/192047A1 |
The present invention pertains to the technical field of herbicide crystallization processes, and particularly relates to an amorphous triazolesulcotrione, a preparation method therefor, and a use thereof. X-ray powder diffraction measur...
|
|
WO/2018/188590A1 |
Fluorine-substituted indazole compounds, pharmaceutical compositions containing these compounds and uses thereof. The compounds and pharmaceutical compositions can be used as soluble guanylate cyclase simulators.
|
|
WO/2018/191283A1 |
Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/177781A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, (I). Th...
|
|
WO/2018/178227A1 |
Disclosed are intermediates and methods of synthesizing Compound 1.
|
|
WO/2018/180943A1 |
The present invention provides an industrially excellent production method which can more efficiently and conveniently produce a halogen-containing pyrazol carboxylic acid and an intermediate thereof which are useful as a pharmaceutical ...
|
|
WO/2018/181456A1 |
Provided is a compound represented by the formula, or a salt thereof, the compound having RORγt-inhibiting activity and being useful as a prophylactic or therapeutic agent for autoimmune or allergic diseases.
|
|
WO/2018/176158A1 |
There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145°C, n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the b...
|
|
WO/2018/180944A1 |
The present invention provides an industrially excellent production method by which a halogenated pyrazolecarboxylic acid useful as an intermediate for medicines and agricultural chemicals can be more easily and efficiently produced. The...
|
|
WO/2018/171602A1 |
Provided are a urea compound having a dual inhibitory activity against IDO and TDO and being represented by the formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and pharmaceutical composition thereof, and a...
|
|
WO/2018/172423A1 |
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...
|
